Global Diagnostic Labs LLC

Global Diagnostic Labs LLC was paid $146K by Medicaid between Aug 2020 and Apr 2023, across 19 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 50% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Georgia

Rank by total paid#35 of 66

Median peer was paid$178K

This provider vs. median0.8×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	2,253	$13K
2021	5,052	$74K
2022	4,090	$57K
2023	80	$2K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	50%	2,702	1,977	$73K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	16%	1,406	949	$24K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	12%	2,049	1,433	$17K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	10%	2,401	1,706	$15K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	4.1%	443	372	$6K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	2.0%	128	120	$3K
86328		1.1%	269	240	$2K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	795	140	$1K
87811	Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19)	<1%	95	55	$1K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	29	26	$970.06
86318		<1%	269	240	$851.72
87640		<1%	155	140	$315.37

7 more codes

87581		<1%	155	$315.37
87498		<1%	129	$252.99
87486		<1%	130	$252.99
87541		<1%	130	$252.99
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	129	$252.99
87634		<1%	29	$62.39
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	32	$58.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialLIPTON, DANNY (OWNER)